Genetic Biomarkers for Risk of CLL Progression among high-count MBLs

$1.83M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Mayo Clinic Rochester
Country	United States
Start Date	Jan 01, 2021
End Date	Sep 30, 2023
Duration	1,002 days
Number of Grantees	2
Roles	Co-Investigator; Principal Investigator
Data Source	NIH (US)
Grant ID	`10321662`

Grant Description

Monoclonal B-cell lymphocytosis (MBL) is a precursor state to chronic lymphocytic leukemia (CLL), and one of the most common premalignant conditions. MBL is present in 5-10% of the adult population over age 40-years (6-12 million U.S. adults) and is an asymptomatic condition that is characterized by an absolute B-cell count